MX2021007939A - Porciones de union a claudina 18.2 y usos de estas. - Google Patents
Porciones de union a claudina 18.2 y usos de estas.Info
- Publication number
- MX2021007939A MX2021007939A MX2021007939A MX2021007939A MX2021007939A MX 2021007939 A MX2021007939 A MX 2021007939A MX 2021007939 A MX2021007939 A MX 2021007939A MX 2021007939 A MX2021007939 A MX 2021007939A MX 2021007939 A MX2021007939 A MX 2021007939A
- Authority
- MX
- Mexico
- Prior art keywords
- binding moieties
- claudin
- chimeric antigen
- antigen receptors
- engineered immune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018125052 | 2018-12-28 | ||
| CN2019095827 | 2019-07-12 | ||
| PCT/CN2019/129017 WO2020135674A1 (en) | 2018-12-28 | 2019-12-27 | Claudin18.2 binding moieties and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007939A true MX2021007939A (es) | 2021-10-22 |
Family
ID=71127698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007939A MX2021007939A (es) | 2018-12-28 | 2019-12-27 | Porciones de union a claudina 18.2 y usos de estas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12258418B2 (https=) |
| EP (1) | EP3902839A4 (https=) |
| JP (2) | JP2022515487A (https=) |
| KR (1) | KR20210110339A (https=) |
| CN (1) | CN113227146B (https=) |
| AU (1) | AU2019415848A1 (https=) |
| BR (1) | BR112021012608A2 (https=) |
| CA (1) | CA3125193A1 (https=) |
| IL (1) | IL284393A (https=) |
| MX (1) | MX2021007939A (https=) |
| SG (1) | SG11202106534RA (https=) |
| WO (1) | WO2020135674A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020228806A1 (zh) * | 2019-05-16 | 2020-11-19 | 齐鲁制药有限公司 | 针对密蛋白18a2的抗体及其应用 |
| BR112022008653A2 (pt) | 2019-11-05 | 2022-07-19 | Lanova Medicines Ltd | Conjugado anticorpo-fármaco, método para tratar câncer, e, uso do conjugado anticorpo-fármaco |
| CN114829408B (zh) | 2019-12-20 | 2024-01-26 | 山东博安生物技术股份有限公司 | 用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂 |
| CN113637082A (zh) * | 2020-04-27 | 2021-11-12 | 启愈生物技术(上海)有限公司 | 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用 |
| WO2022002112A1 (en) | 2020-07-01 | 2022-01-06 | Shandong Boan Biotechnology Co., Ltd. | Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody |
| CN113929780A (zh) * | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| EP4217396A4 (en) * | 2020-09-28 | 2025-06-18 | Elpiscience (Suzhou) Biopharma, Ltd. | NEW ANTI-CLAUDIN18 ANTIBODIES |
| IL302402A (en) | 2020-11-08 | 2023-06-01 | Seagen Inc | Combined treatment |
| CN114560941B (zh) * | 2020-11-27 | 2024-01-16 | 广东东阳光药业股份有限公司 | Cldn18.2的抗体及其应用 |
| CN114539402B (zh) * | 2020-11-27 | 2025-06-13 | 南京北恒生物科技有限公司 | 靶向Claudin18.2的抗体及其用途 |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| CA3199830A1 (en) | 2020-12-23 | 2022-06-30 | Lukas BAMMERT | Tumor-specific claudin 18.2 antibody-drug conjugates |
| CN113321730B (zh) * | 2021-01-11 | 2023-10-10 | 上海莱馥医疗科技有限公司 | Cldn18.2抗体及其应用 |
| US20240117035A1 (en) * | 2021-02-08 | 2024-04-11 | Shandong Boan Biotechnology Co., Ltd. | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors |
| CN115109154A (zh) * | 2021-03-17 | 2022-09-27 | 三优生物医药(上海)有限公司 | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 |
| EP4299593A4 (en) * | 2021-04-02 | 2025-12-10 | Oricell Therapeutics Co Ltd | CLDN18.2 ANTIGEN-BINDING PROTEIN AND ITS USE |
| CN117157105A (zh) * | 2021-05-08 | 2023-12-01 | 荣昌生物制药(烟台)股份有限公司 | 一种抗Claudin18.2抗体及其抗体药物偶联物 |
| EP4488290A1 (en) | 2022-03-04 | 2025-01-08 | ABTIS Co., Ltd. | Method for increasing production yield of antibody-drug conjugate by using thiol-reactive additive |
| WO2024096564A1 (ko) | 2022-11-01 | 2024-05-10 | 앱티스 주식회사 | 항-클라우딘18.2 항체를 포함하는 항체-약물 컨쥬게이트 및 이의 암에 대한 치료용도 |
| KR20250129814A (ko) | 2023-01-18 | 2025-08-29 | 타이리간드 바이오사이언스 (상하이) 리미티드 | 항체-약물 접합체 및 이의 용도 |
| CN116284224B (zh) * | 2023-05-12 | 2023-07-25 | 中国农业大学 | 一种结合Claudin 18.2的环肽及其应用 |
| WO2025038602A1 (en) * | 2023-08-14 | 2025-02-20 | Ginkgo Bioworks, Inc. | Immune cell stimulatory sequences |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025072299A1 (en) * | 2023-09-25 | 2025-04-03 | Duke University | Compositions comprising hiv envelopes to induce hiv-1 antibodies |
| CN120829517A (zh) * | 2024-04-22 | 2025-10-24 | 鲁南新时代生物技术有限公司 | 抗cldn18.2/cd3双特异性抗体及用途 |
| WO2025251228A1 (en) | 2024-06-05 | 2025-12-11 | Nuwacell Biotechnologies Co., Ltd. | Cldn18.2-targeting chimeric antigen receptor and engineered cell |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174403A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN120137055A (zh) * | 2014-07-17 | 2025-06-13 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| AU2017294276B2 (en) * | 2016-07-08 | 2024-08-01 | Crage Medical Co., Limited | Antibody for anti-claudin 18A2 and use thereof |
| JP7398380B2 (ja) * | 2018-03-08 | 2023-12-14 | フェインズ セラピューティクス，インコーポレーテッド | 抗クローディン１８．２抗体及びその使用 |
| SG11202007074PA (en) * | 2018-05-18 | 2020-08-28 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
| CA3128502A1 (en) * | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
| WO2021032157A1 (en) * | 2019-08-20 | 2021-02-25 | Mabspace Biosciences (Suzhou) Co., Limited | Novel anti-cldn18.2 antibodies |
-
2019
- 2019-12-27 CN CN201980085449.3A patent/CN113227146B/zh active Active
- 2019-12-27 JP JP2021537771A patent/JP2022515487A/ja active Pending
- 2019-12-27 KR KR1020217023724A patent/KR20210110339A/ko active Pending
- 2019-12-27 EP EP19906510.3A patent/EP3902839A4/en active Pending
- 2019-12-27 CA CA3125193A patent/CA3125193A1/en active Pending
- 2019-12-27 SG SG11202106534RA patent/SG11202106534RA/en unknown
- 2019-12-27 MX MX2021007939A patent/MX2021007939A/es unknown
- 2019-12-27 US US17/419,203 patent/US12258418B2/en active Active
- 2019-12-27 BR BR112021012608-2A patent/BR112021012608A2/pt unknown
- 2019-12-27 AU AU2019415848A patent/AU2019415848A1/en active Pending
- 2019-12-27 WO PCT/CN2019/129017 patent/WO2020135674A1/en not_active Ceased
-
2021
- 2021-06-27 IL IL284393A patent/IL284393A/en unknown
-
2024
- 2024-06-26 JP JP2024103100A patent/JP7724332B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3902839A1 (en) | 2021-11-03 |
| JP2024125370A (ja) | 2024-09-18 |
| CA3125193A1 (en) | 2020-07-02 |
| SG11202106534RA (en) | 2021-07-29 |
| JP7724332B2 (ja) | 2025-08-15 |
| JP2022515487A (ja) | 2022-02-18 |
| CN113227146A (zh) | 2021-08-06 |
| AU2019415848A8 (en) | 2021-09-02 |
| EP3902839A4 (en) | 2022-12-14 |
| CN113227146B (zh) | 2024-03-01 |
| US20220073643A1 (en) | 2022-03-10 |
| US12258418B2 (en) | 2025-03-25 |
| AU2019415848A1 (en) | 2021-08-19 |
| BR112021012608A2 (pt) | 2021-09-08 |
| WO2020135674A1 (en) | 2020-07-02 |
| IL284393A (en) | 2021-08-31 |
| KR20210110339A (ko) | 2021-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007939A (es) | Porciones de union a claudina 18.2 y usos de estas. | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| MX2022015823A (es) | Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos. | |
| MX2025015210A (es) | Receptores de antigeno quimericos dirigidos a cd70 | |
| PH12019502637A1 (en) | Chimeric antigen receptors targeting flt3 | |
| ZA202006943B (en) | Chimeric receptors to dll3 and methods of use thereof | |
| ZA202007393B (en) | Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy | |
| MX2024010239A (es) | Receptores de antigenos quimericos dirigidos a bcma y metodos de uso de estos. | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| NZ782442A (en) | Antibodies that bind cd39 and uses thereof | |
| MX420258B (es) | Proteínas de unión a nkg2d, cd16 y nectina 4. | |
| PH12018502478A1 (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
| MX2020002036A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. | |
| EP4527466A3 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
| ZA201807920B (en) | Anti¿gitr antibodies and uses thereof | |
| MX2023010499A (es) | Anticuerpos heterodimericos que se unen a cd3 y cldn6. | |
| MX2020001257A (es) | Proteinas que se unen a nkg2d, cd16 y flt3. | |
| PH12021552790A1 (en) | Materials and methods for modulating t cell mediated immunity | |
| AU2018338423A1 (en) | Novel anti-HLA-A2 antibodies and uses thereof | |
| SA521421049B1 (ar) | مستقبلات خيمرية لمستضدات بشروية ستة عبر الغشاء للبروستاتة 1 وطرق استخدامها | |
| PH12019550194A1 (en) | Anti-ceacam1 antibody and use thereof | |
| PH12022550035A1 (en) | Antibodies which bind to cancer cells and target radionuclides to said cells | |
| EA202191821A1 (ru) | Группы, связывающие клаудин 18.2, и их использование |